Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines. Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured, according to a release from the company.
Read More
